I guess we dont know exact start date but surely results by christmas??
The Phase I/II topical study will assess RECCE 327 as a broad-spectrum antibiotic for patients with Gram-positive and Gram-negative bacterial burn wound infections.
The trial will involve up to 30 patients to assess safety and efficacy of RECCE 327 before expanding to a comparative effectiveness study based on the data. Over 14 days, 10 patients wil receive RECCE 327 daily while a further 20 receive treatment three times per week.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)